Amarin (NASDAQ:AMRN) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Amarin (NASDAQ:AMRNFree Report) from a hold rating to a buy rating in a report released on Monday morning.

Amarin Stock Performance

NASDAQ:AMRN opened at $0.73 on Monday. The stock has a fifty day moving average price of $0.85 and a 200-day moving average price of $0.96. Amarin has a fifty-two week low of $0.63 and a fifty-two week high of $1.49. The company has a market cap of $299.83 million, a price-to-earnings ratio of -6.08 and a beta of 1.98.

Amarin (NASDAQ:AMRNGet Free Report) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. The firm had revenue of $56.52 million during the quarter, compared to the consensus estimate of $51.34 million. Amarin had a negative return on equity of 9.48% and a negative net margin of 18.96%. During the same period last year, the company earned ($0.04) earnings per share. Research analysts predict that Amarin will post -0.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AMRN. Significant Wealth Partners LLC raised its stake in Amarin by 128.7% during the 1st quarter. Significant Wealth Partners LLC now owns 34,582 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 19,461 shares during the period. Newbridge Financial Services Group Inc. bought a new position in shares of Amarin in the first quarter valued at $37,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Amarin by 351.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 34,725 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Amarin by 100.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 23,313 shares during the last quarter. Finally, SVB Wealth LLC increased its position in shares of Amarin by 100.0% during the fourth quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 30,000 shares in the last quarter. 22.25% of the stock is owned by institutional investors and hedge funds.

Amarin Company Profile

(Get Free Report)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Recommended Stories

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.